When TP53-mutated clones appear during the disease course would be important to determine, as their early detection in myeloid malignancies could allow to target them pharmacologically, potentially preventing progression to full-blown biallelic TP53 MDS/AML. The gene discussed is TP53; the disease is myeloid neoplasm.